GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carna Biosciences Inc (TSE:4572) » Definitions » Gross-Profit-to-Asset %

Carna Biosciences (TSE:4572) Gross-Profit-to-Asset % : 10.43% (As of Jun. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Carna Biosciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Carna Biosciences's annualized Gross Profit for the quarter that ended in Jun. 2024 was 円395 Mil. Carna Biosciences's average Total Assets over the quarter that ended in Jun. 2024 was 円3,790 Mil. Therefore, Carna Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 10.43%.


Carna Biosciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Carna Biosciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carna Biosciences Gross-Profit-to-Asset % Chart

Carna Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.95 18.43 36.66 25.06 33.67

Carna Biosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.15 15.51 80.82 13.02 10.43

Competitive Comparison of Carna Biosciences's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Carna Biosciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Gross-Profit-to-Asset % falls into.



Carna Biosciences Gross-Profit-to-Asset % Calculation

Carna Biosciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=1450.595/( (4266.453+4349.891)/ 2 )
=1450.595/4308.172
=33.67 %

Carna Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=395.252/( (3894.22+3685.65)/ 2 )
=395.252/3789.935
=10.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Carna Biosciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Carna Biosciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Carna Biosciences Business Description

Traded in Other Exchanges
N/A
Address
BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.

Carna Biosciences Headlines

No Headlines